Assaf Issachar

1.4k total citations
27 papers, 620 citations indexed

About

Assaf Issachar is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Assaf Issachar has authored 27 papers receiving a total of 620 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hepatology, 15 papers in Epidemiology and 7 papers in Surgery. Recurrent topics in Assaf Issachar's work include Liver Disease Diagnosis and Treatment (13 papers), Liver Disease and Transplantation (8 papers) and Hepatitis C virus research (7 papers). Assaf Issachar is often cited by papers focused on Liver Disease Diagnosis and Treatment (13 papers), Liver Disease and Transplantation (8 papers) and Hepatitis C virus research (7 papers). Assaf Issachar collaborates with scholars based in Israel, United States and Canada. Assaf Issachar's co-authors include Amir Shlomai, Noam Peleg, Marius Braun, Michal Cohen‐Naftaly, Ibrahim Marai, Michael Shechter, Yael Shahar, Nira Koren‐Morag, Micha S. Feinberg and Alon Shechter and has published in prestigious journals such as Journal of the American College of Cardiology, PLoS ONE and Scientific Reports.

In The Last Decade

Assaf Issachar

26 papers receiving 607 citations

Peers

Assaf Issachar
Signe Wiese Denmark
John H. Helzberg United States
Ivan Jakopčić Croatia
Preya Patel Australia
Amedeo Ligabue Italy
Moreshwar S. Desai United States
Martha H. Ramos Mexico
F.J. Carrilho Brazil
Kiyotaka Kurose Japan
Sangbin Han South Korea
Signe Wiese Denmark
Assaf Issachar
Citations per year, relative to Assaf Issachar Assaf Issachar (= 1×) peers Signe Wiese

Countries citing papers authored by Assaf Issachar

Since Specialization
Citations

This map shows the geographic impact of Assaf Issachar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Assaf Issachar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Assaf Issachar more than expected).

Fields of papers citing papers by Assaf Issachar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Assaf Issachar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Assaf Issachar. The network helps show where Assaf Issachar may publish in the future.

Co-authorship network of co-authors of Assaf Issachar

This figure shows the co-authorship network connecting the top 25 collaborators of Assaf Issachar. A scholar is included among the top collaborators of Assaf Issachar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Assaf Issachar. Assaf Issachar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Gabbay, Uri, et al.. (2022). Gender specific survival rates after deceased donor liver transplantation: A retrospective cohort. Annals of Medicine and Surgery. 79. 103933–103933. 6 indexed citations
3.
Shafran, Noa, Assaf Issachar, Tzippy Shochat, et al.. (2021). Abnormal liver tests in patients with SARS-CoV-2 or influenza – prognostic similarities and temporal disparities. JHEP Reports. 3(3). 100258–100258. 21 indexed citations
4.
Houri, Inbal, Ziv Ben‐Ari, Amir Shlomai, et al.. (2020). Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial. BMC Infectious Diseases. 20(1). 264–264. 5 indexed citations
5.
Schmilovitz‐Weiss, Hemda, Doron Boltin, David Groshar, et al.. (2020). [¹¹C] choline as a potential PET/CT biomarker of liver cirrhosis: A prospective pilot study. Digestive and Liver Disease. 53(6). 753–759. 1 indexed citations
6.
Etzion, Ohad, Harel Dahari, David Yardeni, et al.. (2020). Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study. Scientific Reports. 10(1). 17820–17820. 12 indexed citations
7.
Peleg, Noam, Assaf Issachar, Michal Cohen‐Naftaly, et al.. (2019). Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load. JHEP Reports. 1(1). 9–16. 52 indexed citations
8.
Aravinthan, Aloysious, Waleed Fateen, Adam Doyle, et al.. (2019). The Impact of Preexisting and Post-transplant Diabetes Mellitus on Outcomes Following Liver Transplantation. Transplantation. 103(12). 2523–2530. 26 indexed citations
9.
Ravid, Amiram, Assaf Issachar, A. Erman, et al.. (2019). 25-Hydroxyvitamin D Inhibits Hepatitis C Virus Production in Hepatocellular Carcinoma Cell Line by a Vitamin D Receptor-Independent Mechanism. International Journal of Molecular Sciences. 20(9). 2367–2367. 12 indexed citations
10.
Peleg, Noam, et al.. (2018). Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease. PLoS ONE. 13(8). e0202393–e0202393. 37 indexed citations
11.
Peleg, Noam, Michal Cohen‐Naftaly, Marius Braun, et al.. (2018). The Pattern of Elevated Liver Function Tests in Nonalcoholic Fatty Liver Disease Predicts Fibrosis Stage and Metabolic-Associated Comorbidities. Digestive Diseases. 37(1). 69–76. 7 indexed citations
12.
Moore, Assaf, Michal Cohen‐Naftaly, Anna Tobar, et al.. (2017). Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma. Radiation Oncology. 12(1). 163–163. 55 indexed citations
13.
Aravinthan, Aloysious, Adam Doyle, Hla‐Hla Thein, et al.. (2017). Liver Transplantation is a Preferable Alternative to Palliative Therapy for Selected Patients with Advanced Hepatocellular Carcinoma. Annals of Surgical Oncology. 24(7). 1843–1851. 16 indexed citations
14.
Issachar, Assaf, et al.. (2017). Occurrence and recurrence of malignancies post DAA Treatment in 5.1% of patients- single center experience. Journal of Hepatology. 66(1). S97–S97. 4 indexed citations
15.
Moore, Assaf, Michal Cohen‐Naftaly, Ofer Benjaminov, et al.. (2016). Radiotherapy and Sorafenib in the Management of Patients with Hepatocellular Carcinoma Have Led to Improved Survival: A Single Center Experience. Journal of Cancer. 7(8). 883–889. 4 indexed citations
16.
Aravinthan, Aloysious, Adam Doyle, Assaf Issachar, et al.. (2016). First-Degree Living-Related Donor Liver Transplantation in Autoimmune Liver Diseases. American Journal of Transplantation. 16(12). 3512–3521. 18 indexed citations
17.
Braun, Marius, et al.. (2016). Yield of magnetic resonance cholangiopancreatography for the investigation of bile duct dilatation in asymptomatic patients. United European Gastroenterology Journal. 5(3). 408–414. 7 indexed citations
18.
Shechter, Michael, Alon Shechter, Nira Koren‐Morag, et al.. (2011). LONG-TERM ASSOCIATION OF BRACHIAL ARTERY FLOW-MEDIATED VASODILATION AND CARDIOVASCULAR EVENTS IN MIDDLE-AGED SUBJECTS WITH NO APPARENT HEART DISEASE. Journal of the American College of Cardiology. 57(14). E1413–E1413. 5 indexed citations
19.
Zemel, Romy, Assaf Issachar, & Ran Tur‐Kaspa. (2011). The Role of Oncogenic Viruses in the Pathogenesis of Hepatocellular Carcinoma. Clinics in Liver Disease. 15(2). 261–279. 34 indexed citations
20.
Shechter, Michael, Assaf Issachar, Ibrahim Marai, et al.. (2008). Long-term association of brachial artery flow-mediated vasodilation and cardiovascular events in middle-aged subjects with no apparent heart disease. International Journal of Cardiology. 134(1). 52–58. 180 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Signe Wiese Breakdown of academic impact, for papers by John H. Helzberg Breakdown of academic impact, for papers by Ivan Jakopčić Breakdown of academic impact, for papers by Preya Patel Breakdown of academic impact, for papers by Amedeo Ligabue Breakdown of academic impact, for papers by Moreshwar S. Desai Breakdown of academic impact, for papers by Martha H. Ramos Breakdown of academic impact, for papers by F.J. Carrilho Breakdown of academic impact, for papers by Kiyotaka Kurose Breakdown of academic impact, for papers by Sangbin Han
Rankless by CCL
2026